Menu
Recruiting NCT03422614

Pathophysiology of Inborn Immunodeficiencies

Observational Primary Immune Deficiency Disorder

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Diagnostic Test.
Who it may be relevant to
Registry conditions: Primary Immune Deficiency Disorder. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Switzerland
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Pathophysiologie Angeborener Immundefekte

Overview

The pathophysiology of primary immunodeficiencies (PID), which encompass a broad range of different diseases with susceptibility to infection and/or a deregulated inflammatory response, is poorly understood. Available treatments are often not specific for a distinct target and might be associated with side effects. To elucidate pathophysiology of different PIDs, stool, urine, blood, tissue biopsies and/or bone marrow will be collected and analysed for anti-microbial activity and inflammatory response. In a second step, targeted treatment for different PIDs might be developed preclinically and ex vivo according to underlying pathophysiology.

Interventions

  • Diagnostic test Diagnostic Test
    Characterisation of cellular and functional phenotype in different PIDs

Primary outcome measures

  • Characterisation of cellular phenotype in different PIDs [Time frame: immediately after sampling of biological specimen or up to 10 years later from frozen samples]
  • Characterisation of functional phenotype in different PIDs [Time frame: immediately after sampling of biological specimen or up to 10 years later from frozen samples]
Secondary outcome measures (1)
  • Identification of potential targets for pathophysiology-specific treatment, or for curative treatment such as gene therapy for different PIDs ex vivo [Time frame: immediately after sampling of biological specimen or up to 10 years later from frozen samples]

Eligibility criteria

Inclusion criteria

  • Clinical diagnosis of an inborn error of immunity (primary immunodeficiency, PID)
  • Clinically healthy (non-age matched) volunteer

Exclusion criteria

  • exclusion of an inborn error of immunity
  • secondary immunodeficiency
  • refusal to enter the study

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Case-control

Study locations

Switzerland · 1 center
  • University Children's Hospital Zurich — Zurich

Identifiers

NCT: NCT03422614 · Patho_PID

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗